Pertuzumab 420mg/14mL (30mg/mL) Infusion$1,232.00
1–9 boxes
$1,232.00 each
10–24 boxes
8% off
25+ boxes
10% off
Pertuzumab 420mg/14mL (30mg/mL) Infusion
SKU GME1347Oncology Care
Product Introduction
Pertuzumab 420mg/14mL (30mg/mL) is a HER2-directed monoclonal antibody used with trastuzumab and chemotherapy in selected HER2-positive breast-cancer regimens.
How to use
The concentrate is diluted and given as an intravenous infusion. Initial and maintenance infusions have different durations, with observation for reactions. It is not a subcutaneous fixed-combination product or an intravenous push.
How it works
Pertuzumab binds the HER2 dimerisation domain, inhibiting pairing with other HER receptors. It complements trastuzumab, which binds a different HER2 region.
Side effects
Diarrhoea, infusion reactions and fatigue can occur. With chemotherapy, neutropenia and hair loss are common. Reduced left-ventricular function is an important serious risk.
Important information
HER2 status and heart function are assessed before treatment, with cardiac monitoring during therapy. Pregnancy must be avoided because of fetal risk.
Uses
- Selected neoadjuvant, adjuvant and metastatic HER2-positive breast-cancer regimens.
Benefits
Dual HER2 blockade can improve response and disease control when added to the appropriate trastuzumab-based regimen.
Is pertuzumab the same as trastuzumab?
No. They bind different HER2 regions and are used together in established regimens.
Does a HER2-negative tumour have the same treatment role?
No. The regimen relies on confirmed HER2-positive disease.
Why is an echocardiogram needed?
HER2-directed treatment can reduce cardiac pumping function, so a baseline and follow-up measurement is important.
Why do I need observation after a pertuzumab infusion?
Infusion reactions can develop while the medicine is running or shortly afterwards. Tell the team immediately about chills, rash, dizziness, swelling or breathing difficulty rather than waiting for the observation period to end.
HER2 dimerisation: pairing of HER-family receptors. Neoadjuvant: treatment before surgery. Left-ventricular function: the pumping ability of the main heart chamber.; AR: Pertuzumab 420mg/14mL (30mg/mL) تسريب وريدي; FR: Pertuzumab 420mg/14mL (30mg/mL) perfusion intraveineuse; PT: Pertuzumab 420mg/14mL (30mg/mL) infusão intravenosa; ES: Pertuzumab 420mg/14mL (30mg/mL) perfusión intravenosa; RU: Pertuzumab 420mg/14mL (30mg/mL) внутривенная инфузия; ID: Pertuzumab 420mg/14mL (30mg/mL) infus intravena; VI: Pertuzumab 420mg/14mL (30mg/mL) thuốc truyền tĩnh mạch; MS: Pertuzumab 420mg/14mL (30mg/mL) infusi intravena; TL: Pertuzumab 420mg/14mL (30mg/mL) pagbubuhos sa ugat; ZH-SG: Pertuzumab 420mg/14mL (30mg/mL) 静脉输注